Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots: The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industryIn December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis PharmaShots has compiled a list of a…

BySaurabh ChaubeyJanuary 23, 2024

VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots: Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…

BySaurabh ChaubeyDecember 5, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Shots:The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industryIn July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancerPharmaShots has compiled a list…

BySenior EditorAugust 24, 2023

THOUGHTSPOT

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Shots:With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. The 2021 data reflects 537M affected people, with the predominant population living in low- and middle-income countriesType 2 diabetes mellitus (T2DM), unlike Type 1 diabetes mellitus (T1DM) is…

BySaurabh ChaubeyApril 13, 2023

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Contact US

OUR INFORMATION

FOLLW US

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

FOLLW US

Sign Up to Our Newsletter